Publication: Healthcare Brew
The article explores the anticipated developments in psychedelic medicine for 2025 following the FDA’s rejection of Lykos’ MDMA-based therapy in 2024. Industry players now aim to recalibrate clinical trials to address FDA concerns and generate reliable data. Thought leaders like Certara’s Dr. Fran Brown highlighted why companies developing psychedelic medicines should focus on learning from Lykos’s missteps.
Year: 2025 年 1 月 13 日
服务
解决方案
Learn more about Clinical Pharmacology Regulatory Strategy
联系我们的团队，探讨 Certara 临床药理学监管策略如何优化您的药物开发计划。我们将为您量身定制专家指导，应对独特挑战。
